Clinical trials: Small Cell and Non-small Cell Lung Cancer
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
Lung Cancer
A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
Patients ≥ 70 years of age with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) frequently do not receive systemic cytotoxic chemotherapy due to concerns regarding their inability to tolerate…
- Trial name
- NCT00370383
- Testing
- Erlotinib, Satraplatin
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Agennix
Non-squamous Non-small-cell Lung Cancer
The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Primary objective： ·To assess the antitumor activity of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC…
- Trial name
- NCT05849246
- Testing
- Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed, Sintilimab+Carboplatin or Cisplatin+Pemetrexed, Tusamitamab ravtansine+Sintilimab
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Non-Small Cell Lung Cancer, EGFR Gene Mutation
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
To assess the efficacy and safety of D-0316 versus Icotinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with locally advanced or Metastatic Non Small Cell Lung Cancer…
- Trial name
- NCT04206072
- Testing
- D-0316 Capsule, Icotinib Hydrochloride Tablets
- Where
- 2 sites in China
- Volunteers
- 362 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Lung Cancer, Non-small Cell Lung Cancer
An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to…
- Trial name
- NCT00721981
- Where
- 8 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol.
- Trial name
- NCT00033722
- Testing
- folic acid, lometrexol
- Where
- 7 sites in United States
- Sponsor
- Tularik
Non Small Cell Lung Cancer, KRAS Activating Mutation
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced…
- Conditions
- Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer
- Trial name
- RAMP204 (NCT05375994)
- Testing
- avutometinib (VS-6766) and adagrasib
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Verastem, Inc.
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20…
- Trial name
- NCT06616766
- Testing
- YH42946
- Where
- 8 sites in United States, South Korea
- Volunteers
- 201 people
- Sponsor
- Yuhan Corporation
Non Small Cell Lung Cancer, Lung Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread.
- Trial name
- ZEAL (NCT00418886)
- Testing
- Vandetanib, Pemetrexed
- Where
- 110 sites in United States, Argentina and 19 more
- Volunteers
- 698 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
GIOTRIF rPMS in Korean Patients With NSCLC
To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Trial name
- NCT02285361
- Testing
- GIOTRIF 20mg, GIOTRIF 40mg, GIOTRIF 30mg
- Where
- South Korea
- Volunteers
- 1,272 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are…
- Trial name
- NCT04613596
- Testing
- Adagrasib, Pembrolizumab
- Where
- 770 sites in United States, Argentina and 45 more
- Volunteers
- 626 people
- Sponsor
- Mirati Therapeutics Inc.
Non Small Cell Lung Cancer
Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer
A prospective, two-arm, non-randomized, concurrently controlled, multi-center, open-label, treat and resect study following patients to 1 year.
- Trial name
- INCITE ES (NCT04732520)
- Testing
- Pulsed electric field treatment using the Aliya System
- Where
- 4 sites in Hong Kong, Netherlands and 1 more
- Volunteers
- 47 people
- Sponsor
- Galvanize Therapeutics, Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung…
- Trial name
- NCT04448379
- Testing
- JMT101
- Where
- 13 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai JMT-Bio Inc.
Carcinoma, Non-Small-Cell Lung
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany. The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns…
- Trial name
- FINN (NCT04794010)
- Where
- Germany
- Volunteers
- 825 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with…
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Trial name
- NCT07154290
- Testing
- Ubamatamab, Marlotamig, Sarilumab
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.